Formulation of mupirocin adsorbed silver nanoparticle with antibiofilm agents for enhancing antibacterial activit
Selliamman, Ravi Mahi Priya
Formulation of mupirocin adsorbed silver nanoparticle with antibiofilm agents for enhancing antibacterial activit - Vol.56(1), Jan-Mar - Karnataka Association of Pharmaceutical Teachers of India (APTI) 2022 - 50-57p.
Introduction: Biofilm is a complex structure of microbiome having different bacterial
colonies or single type of cells in a group, adhere to the surface to produce infections.
Nanoparticles (NPs) are widely used in different technological fields especially medicine
because of their antibacterial properties. Silver nanoparticles (AgNPs) possess
antimicrobial and antibiofilm property against various microbial infections. Objectives:
The main objective of this study was to develop new formulations and characterization
of mupirocin loaded silver nanoparticles with various anti biofilm agents. Methods: Silver
nanoparticles formulations were prepared by tannic acid (TA) with trisodium citrate
(TSC), Para-amino salicylic acid (PASA) and ascorbic acid (ASC) as both reducing and
antibiofilm agents against
Staphylococcus aureus followed by surface adsorption of
Mupirocin (MUP). Transmission Electron Microscope (TEM) shows that the nanoparticles
are roughly spherical in shape which was also confirmed by Atomic Force Microscopy
(AFM). The particle size was in the range between 50 nm – 250 nm and found to be
statistically significant (
p<0.001) between the three AgNP formulations.
In vitro drug
release using the dialysis membrane showed a maximum release of 90% ± 2.343 in
AgNPs (TSC TA) formulation at the end of 7 hr with the maximum drug entrapment
of 93.75%. The formulations were tested for antimicrobial activity against
S. aureus.
The results were statistically compared using one way ANOVA and student t test.
Conclusion: There is no significant difference in antibacterial activity between three
AgNP formulations. However the best synergistic activity against planktonic
S. aureus
bacteria was shown by AgNP-PASA inspite of its minimal drug release when compared
to AgNPs (TSC TA).
PHARMACEUTICS
Formulation of mupirocin adsorbed silver nanoparticle with antibiofilm agents for enhancing antibacterial activit - Vol.56(1), Jan-Mar - Karnataka Association of Pharmaceutical Teachers of India (APTI) 2022 - 50-57p.
Introduction: Biofilm is a complex structure of microbiome having different bacterial
colonies or single type of cells in a group, adhere to the surface to produce infections.
Nanoparticles (NPs) are widely used in different technological fields especially medicine
because of their antibacterial properties. Silver nanoparticles (AgNPs) possess
antimicrobial and antibiofilm property against various microbial infections. Objectives:
The main objective of this study was to develop new formulations and characterization
of mupirocin loaded silver nanoparticles with various anti biofilm agents. Methods: Silver
nanoparticles formulations were prepared by tannic acid (TA) with trisodium citrate
(TSC), Para-amino salicylic acid (PASA) and ascorbic acid (ASC) as both reducing and
antibiofilm agents against
Staphylococcus aureus followed by surface adsorption of
Mupirocin (MUP). Transmission Electron Microscope (TEM) shows that the nanoparticles
are roughly spherical in shape which was also confirmed by Atomic Force Microscopy
(AFM). The particle size was in the range between 50 nm – 250 nm and found to be
statistically significant (
p<0.001) between the three AgNP formulations.
In vitro drug
release using the dialysis membrane showed a maximum release of 90% ± 2.343 in
AgNPs (TSC TA) formulation at the end of 7 hr with the maximum drug entrapment
of 93.75%. The formulations were tested for antimicrobial activity against
S. aureus.
The results were statistically compared using one way ANOVA and student t test.
Conclusion: There is no significant difference in antibacterial activity between three
AgNP formulations. However the best synergistic activity against planktonic
S. aureus
bacteria was shown by AgNP-PASA inspite of its minimal drug release when compared
to AgNPs (TSC TA).
PHARMACEUTICS